Form 4: Dianthus Therapeutics Director Receives Stock Option Grant

Director Steven J. Romano was granted 6,090 stock options in Dianthus Therapeutics, Inc. as part of an equity incentive.

Summary

• Director Steven J. Romano received a grant of 6,090 stock options on May 21, 2026.
• The options have an exercise price of $89.63 per share.
• The options are set to expire on May 21, 2036.
• The award vests in full on the earlier of the first anniversary of the grant date or the 2027 Annual Meeting of Stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• Results in potential future dilution for existing shareholders upon exercise of the options.

Risks

• Vesting is contingent upon the director's continued service to the issuer.

Future Outlook

The options vest in full on the earlier of May 21, 2027, or the date of the 2027 Annual Meeting of Stockholders, provided the director remains in service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to ensure board alignment with corporate performance and long-term strategic goals.

Comparison to Industry Standards

• The grant of stock options to directors is consistent with standard compensation practices for mid-cap biotechnology firms.
• Vesting schedules tied to annual meetings or one-year anniversaries are common benchmarks for director equity awards.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of the 6,090 stock options on the earlier of May 21, 2027, or the 2027 Annual Meeting of Stockholders.

Key Dates

Keywords

Dianthus Therapeutics, DNTH, Form 4, Insider Trading, Stock Options, Equity Compensation